Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

V. Pollack, Charles; Reilly, Paul; van Ryn, Joanne; W. Eikelboom, John; Glund, Stephan; A. Bernstein, Richard; Dubiel, Robert; V. Huisman, Menno; M. Hylek, Elaine; Kam, CW; W. Kamphuisen, Pieter; Kreuzer, Jörg; H. Levy, Jerrold; Royle, Gordon; W. Sellke, Frank; Stangier, Joachim; Steiner, Thorsten; Verhamme, Peter; Wang, Bushi; Young, Laura; I. Weitz, Jeffrey

doi:10.1056/nejmoa1707278

Public

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Published in New England Journal of Medicine • Jul 11, 2017

Authors:

Charles V. Pollack

Paul Reilly

Joanne van Ryn

Abstract

BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant effect of dabi...

Subject

Medicine

Dabigatran

Idarucizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!